GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (STU:82F) » Definitions » EV-to-EBIT

NFL Biosciences (STU:82F) EV-to-EBIT : -5.07 (As of Jun. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NFL Biosciences's Enterprise Value is €20.80 Mil. NFL Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.11 Mil. Therefore, NFL Biosciences's EV-to-EBIT for today is -5.07.

The historical rank and industry rank for NFL Biosciences's EV-to-EBIT or its related term are showing as below:

STU:82F' s EV-to-EBIT Range Over the Past 10 Years
Min: -13.84   Med: 0   Max: 0
Current: -5.07
STU:82F's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.61 vs STU:82F: -5.07

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NFL Biosciences's Enterprise Value for the quarter that ended in Dec. 2023 was €8.32 Mil. NFL Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.11 Mil. NFL Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -49.38%.

NFL Biosciences EV-to-EBIT Historical Data

The historical data trend for NFL Biosciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NFL Biosciences EV-to-EBIT Chart

NFL Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - -8.44 -3.20 -2.24

NFL Biosciences Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial -8.44 - -3.20 - -2.24

Competitive Comparison of NFL Biosciences's EV-to-EBIT

For the Biotechnology subindustry, NFL Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NFL Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NFL Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NFL Biosciences's EV-to-EBIT falls into.


NFL Biosciences EV-to-EBIT Calculation

NFL Biosciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=20.798/-4.106
=-5.07

NFL Biosciences's current Enterprise Value is €20.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NFL Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NFL Biosciences  (STU:82F) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NFL Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-4.106/8.3150041
=-49.38 %

NFL Biosciences's Enterprise Value for the quarter that ended in Dec. 2023 was €8.32 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NFL Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-4.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NFL Biosciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NFL Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NFL Biosciences (STU:82F) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (STU:82F) » Definitions » EV-to-EBIT
Comparable Companies
XPAR:ALTHX XPAR:ALPAT XPAR:ALHYG XPAR:ALINT XPAR:FALG XPAR:POXEL XPAR:ALVET XPAR:ALBPS XPAR:ALMDP XPAR:ALQGC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
ALNFL:France 82F:Germany
Address
199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170
Website
https://www.nflbiosciences.com/
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (STU:82F) Headlines

No Headlines